Language

Respero Myrtol forte 300 mg — packaging
Packaging may differ

Respero Myrtol forte 300 mg prices in Yerevan pharmacies

distillate of a mixture of rectified essential oils of eucalyptus, sweet orange, myrtle and lemon · capsules gastro-resistant, soft · 300 mg · over the counter

G. Pohl-Boskamp GmbH & Co.KG · Germany

Registration No. 20614/1/1 · valid until 12 Apr 2027

  • Over the counter

Prices at 6 online pharmacies

20 pcs · by pack price · prices from pharmacy websites as of 15 Oct 2026

in stock · out of stock · no mark — the pharmacy does not report stock⁠About these prices

These are prices of the pharmacy chains' online shops, not of a particular branch. The list is sorted by pack price; pharmacies where the medicine is out of stock come last.

“≈ … per unit” is Medaro’s calculation: the pack price divided by the number of units (for liquids and ointments — per 10 ml or 10 g), rounded.

Medaro does not sell medicines and is not paid by pharmacies for their place in the list.

Medaro does not sell medicines and is not paid by pharmacies for their place in the list.

Product record

Trade name
Respero Myrtol forte
Active ingredient (INN)
distillate of a mixture of rectified essential oils of eucalyptus, sweet orange, myrtle and lemon
ATC code
R05C
Registration certificate
No. 20614/1/1,
Dispensing
Over the counter

The register has no link to the official leaflet yet — read the leaflet in the pack.

State Register of Medicines (pharm.am) (opens in a new tab)
Show all detailsHide details
Dosage form
capsules gastro-resistant, soft
Strength
300 mg
Marketing authorisation holder
G. Pohl-Boskamp GmbH & Co.KG, Kieler Strasse 11, 25551, Hohenlockstedt, Germany
Manufacturer
G. Pohl-Boskamp GmbH & Co.KG, Kieler Strasse 11, 25551, Hohenlockstedt- quality control (microbiological), batch releaser, G. Pohl-Boskamp GmbH & Co.KG, Kaddenbusch, 25578, Daegeling, Germany- bulk manufacturer, packager, quality control (physicochemical)
Country
Germany

Details from the State Register of Medicines of Armenia as of 31 Aug 2026. No indications, directions for use or dosing regimen here — read the official leaflet.

Spotted an error? Let us know

As a rule, we will send you a confirmation that your message has been received and, once the check is done, its outcome. We need your address only for emails about this message: it is not published on the site and is not added to any mailing list. Privacy policy